Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

VIR vs ANNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VIR Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

VIR Overall Winner 6-Pillar Tally: VIR 4 – 2 ANNX Matrix Metrics: VIR 7 – 3 ANNX

As of Nov 17, 2026, Vir Biotechnology, Inc. (VIR) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). VIR carries a Unified Composite Score of 46.2/100 (HOLD) at $9.25 (4.3x Forward P/E, -70.2% operating margin), whereas ANNX carries 43.5/100 (HOLD) at $3.47 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: VIR is currently in a Breakdown options structure phase (RSI 37.4); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VIR vs ANNX
VIR NASDAQ Head-to-Head Winner
Vir Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.25
-3.44% 1D
Market Cap $1.7B
TTM Revenue $303M
Forward P/E 4.3x
Beta / 30D Vol 1.75β · 101% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 37.0 Fund 54.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 37
RSI-14: 37.4 · SMA20: $11.36 · SMA50: $11.07
ANNX NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.47
-2.8% 1D
Market Cap $747.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.70β · 63% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 37.0 Fund 55.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.2%), weak momentum, RSI 36
RSI-14: 36.3 · SMA20: $3.96 · SMA50: $3.98

6-Pillar Scorecard Institutional Category Breakdown (VIR 4 – 2 ANNX)

Columns: Metric · VIR · ANNX
1. Valuation Multiples VIR
Forward P/E 4.3x N/M
Trailing P/E 4.3x N/M
PEG Ratio N/M N/M
EV / Revenue 5.2x N/M
2. Growth & Scale VIR
Revenue Growth (YoY) +19582.5% +0.0%
Earnings Growth (YoY) +58.5% +0.0%
TTM Revenue (USD) $303M N/A
Market Cap $1.7B $747.8M
3. Profitability & Quality ANNX
Gross Margin -36.7% N/A
Operating Margin -70.2% 0.0%
Net Profit Margin -61.0% 0.0%
Return on Equity (ROE) -21.8% -130.8%
4. Balance Sheet & Cash Flow VIR
Cash Generation (TTM) -$142M -$190M
Cash Flow Margin -46.8% N/A
Net Cash / Leverage $128M Net Cash $29M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANNX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 65.5% (5th %ile) 569.3% (100th %ile)
Put/Call OI Skew 0.22x (Call-Skewed) 0.09x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat VIR
OpEx & R&D Intensity 33.5% of Rev ($101M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VIR (7) vs ANNX (3)
Institutional Metric VIR ANNX Criterion Row Edge
Market Capitalization
Scale
$1.7B $747.8M Larger Scale VIR
Trailing P/E Ratio
Valuation
4.3x N/M Lower Multiple VIR
Forward P/E Ratio
Valuation
4.3x N/M Lower Multiple VIR
Revenue Growth (YoY)
Growth
+19582.5% +0.0% Higher Growth VIR
Operating Margin (TTM)
Profitability
-70.2% 0.0% Higher Margin ANNX
Net Profit Margin
Profitability
-61.0% 0.0% Higher Margin ANNX
Return on Equity (ROE)
Capital Efficiency
-21.8% -130.8% Higher ROE VIR
52-Week Range Position
Momentum
43% ($5–$14) 18% ($3–$7) Stronger Trend VIR
Beta / 30D Volatility
Risk Regime
1.75β · 101% Vol 1.70β · 63% Vol Lower Realized Risk ANNX
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite VIR
Trailing 12M Revenue (USD)
Operating Scale
$303M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-36.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$142M ($128M Net Cash) -$190M ($29M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIR +4.07 pp
VIR: -9.4% · ANNX: -13.47%
3M Horizon VIR +31.59 pp
VIR: -5.32% · ANNX: -36.91%
6M Horizon VIR +37.77 pp
VIR: +8.44% · ANNX: -29.33%
1Y Horizon VIR +36.26 pp
VIR: +64.3% · ANNX: +28.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VIR vs ANNX. Trailing 12-month operating profitability (VIR -70.2% vs ANNX 0.0%) and valuation multiples (VIR 4.3x vs ANNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VIR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$303M
Gross Margin-36.7%
Op. Margin-70.2%
ROE / Fwd P/E-21.8% · 4.3x
ANNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-130.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VIR BREAKDOWN
6d in phase · OBV DISTRIBUTION
Current IV 65.5%
IV Percentile 5th %ile
Put/Call OI Skew 0.22x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact VIR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANNX BREAKDOWN
88d in phase · OBV DISTRIBUTION
Current IV 569.3%
IV Percentile 100th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $9.58 · IV 64.3%

VIR Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($958)

Compare $958 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 64.3% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $10 / $11 Bull Call Spread

Buy 4x $10C · Sell 4x $11C · 32d

Net Entry $180 Debit
T+5d @ +5% Move +$23 (+13%)
Max Risk / Buffer $180 Capped
5d Edge & Liquidity 0.5x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Dec 18 $9 / $8 Bull Put Spread

Sell 4x $9P · Buy 4x $8P · 32d

Net Entry $92 Credit
Max Credit / Yield +$92 (+29.9% RoM)
Max Risk / Buffer -8.5% Cushion ($308 Mgn)
5d Edge & Liquidity 67% PoP · Liq C
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $10 / $9 Bear Put Spread

Buy 2x $10P · Sell 2x $9P · 32d

Net Entry $94 Debit
T+5d @ -5% Drop +$24 (+25%)
Max Risk / Buffer $94 Capped
5d Edge & Liquidity 0.9x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VIR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -70.2% operating margin.
OpEx & R&D Reinvestment 33.5% of Rev ($101M)
90D Engineering Disclosures 0 Published
ANNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $747.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VIR vs ANNX Key Questions & Quantitative Answers

As of Nov 17, 2026, Vir Biotechnology, Inc. (VIR) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). VIR carries a Unified Composite Score of 46.2/100 (HOLD) at $9.25 (4.3x Forward P/E, -70.2% operating margin), whereas ANNX carries 43.5/100 (HOLD) at $3.47 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: VIR is currently in a Breakdown options structure phase (RSI 37.4); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VIR leads the Growth & Scale pillar: VIR posts +19582.5% YoY revenue growth and +58.5% YoY earnings growth on $303M TTM revenue (-36.7% gross margin, -70.2% operating margin), compared with ANNX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VIR generates $303M in USD-normalized revenue versus N/A for ANNX. In operating R&D and SG&A reinvestment, VIR deploys 33.5% of Rev ($101M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANNX.

VIR screens cheaper on headline valuation multiples. VIR trades at 4.3x Forward P/E, 4.3x Trailing P/E, N/M PEG, and 5.2x EV/Revenue (-46.8% FCF margin), whereas ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIR (-21.8% ROE) versus ANNX (-130.8% ROE) capital efficiency.

In options market volatility and institutional positioning, VIR carries 65.5% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.22x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.75β · 101% Vol realized risk). By comparison, ANNX carries 569.3% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.